BACKGROUND: The aim of the present study was to evaluate the prognostic significance of the Glasgow Prognostic Score (GPS) in metastatic renal cell carcinoma (mRCC) patients treated by cytoreductive nephrectomy (CN), and the accuracy of the GPS as a prognostic factor. METHODS: We retrospectively analyzed the data of patients who underwent CN for mRCC between March 1984 and August 2015. In accordance with the GPS criteria, the patients were classified into three groups: GPS 0: C-reactive protein (CRP) ≤ 1.0 mg/dl and albumin ≥ 3.5 g/dl; GPS 1: CRP > 1.0 mg/dl or albumin < 3.5 g/dl; and GPS 2: CRP > 1.0 mg/dl and albumin < 3.5 g/dl. RESULTS: We enrolled 170 patients (72% male; median age 63.5 years). Fifty-six (33%), 67 (39%), and 47 (28%) patients had a GPS of 0, 1, and 2, respectively. The median overall survivals after CN were 52.4, 19.1, and 8.9 months for patients with a GPS of 0, 1, and 2, respectively (P < 0.0001). In addition to the GPS, Eastern Cooperative Oncology Group performance status (ECOG-PS), Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis were included in the Cox hazards regression model. Multivariate analysis of these factors revealed that the GPS was an independent prognostic factor of overall survival (P < 0.0001). Harrell's concordance index in the multivariate prognostic model based on ECOG-PS, MSKCC risk criteria, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis was 0.609, which increased to 0.652 after the inclusion of the GPS. CONCLUSIONS: GPS represents an independent prognostic factor for patients who undergo CN for mRCC.
BACKGROUND: The aim of the present study was to evaluate the prognostic significance of the Glasgow Prognostic Score (GPS) in metastatic renal cell carcinoma (mRCC) patients treated by cytoreductive nephrectomy (CN), and the accuracy of the GPS as a prognostic factor. METHODS: We retrospectively analyzed the data of patients who underwent CN for mRCC between March 1984 and August 2015. In accordance with the GPS criteria, the patients were classified into three groups: GPS 0: C-reactive protein (CRP) ≤ 1.0 mg/dl and albumin ≥ 3.5 g/dl; GPS 1: CRP > 1.0 mg/dl or albumin < 3.5 g/dl; and GPS 2: CRP > 1.0 mg/dl and albumin < 3.5 g/dl. RESULTS: We enrolled 170 patients (72% male; median age 63.5 years). Fifty-six (33%), 67 (39%), and 47 (28%) patients had a GPS of 0, 1, and 2, respectively. The median overall survivals after CN were 52.4, 19.1, and 8.9 months for patients with a GPS of 0, 1, and 2, respectively (P < 0.0001). In addition to the GPS, Eastern Cooperative Oncology Group performance status (ECOG-PS), Memorial Sloan-Kettering Cancer Center (MSKCC) risk classification, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis were included in the Cox hazards regression model. Multivariate analysis of these factors revealed that the GPS was an independent prognostic factor of overall survival (P < 0.0001). Harrell's concordance index in the multivariate prognostic model based on ECOG-PS, MSKCC risk criteria, histology, sarcomatoid change, clinical T stage, primary tumor size, number of metastatic organs, non-regional lymph node metastasis, and liver metastasis was 0.609, which increased to 0.652 after the inclusion of the GPS. CONCLUSIONS: GPS represents an independent prognostic factor for patients who undergo CN for mRCC.
Authors: R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford Journal: N Engl J Med Date: 2001-12-06 Impact factor: 91.245
Authors: Toni K Choueiri; Wanling Xie; Christian Kollmannsberger; Scott North; Jennifer J Knox; J Geoffrey Lampard; David F McDermott; Brian I Rini; Daniel Y C Heng Journal: J Urol Date: 2010-11-12 Impact factor: 7.450
Authors: A S Koo; C Armstrong; B Bochner; T Shimabukuro; C L Tso; J B deKernion; A Belldegrum Journal: Cancer Immunol Immunother Date: 1992 Impact factor: 6.968
Authors: Vitaly Margulis; Shahrokh F Shariat; Yury Rapoport; Michael Rink; Daniel D Sjoberg; Nizar M Tannir; E Jason Abel; Stephen H Culp; Pheroze Tamboli; Christopher G Wood Journal: Eur Urol Date: 2012-11-23 Impact factor: 20.096
Authors: Stephen H Culp; Nizar M Tannir; E Jason Abel; Vitaly Margulis; Pheroze Tamboli; Surena F Matin; Christopher G Wood Journal: Cancer Date: 2010-07-15 Impact factor: 6.860
Authors: Daniel Y C Heng; J Connor Wells; Brian I Rini; Benoit Beuselinck; Jae-Lyun Lee; Jennifer J Knox; Georg A Bjarnason; Sumanta Kumar Pal; Christian K Kollmannsberger; Takeshi Yuasa; Sandy Srinivas; Frede Donskov; Aristotelis Bamias; Lori A Wood; D Scott Ernst; Neeraj Agarwal; Ulka N Vaishampayan; Sun Young Rha; Jenny J Kim; Toni K Choueiri Journal: Eur Urol Date: 2014-06-13 Impact factor: 20.096
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Lauren C Harshman; Georg A Bjarnason; Ulka N Vaishampayan; Mary Mackenzie; Lori Wood; Frede Donskov; Min-Han Tan; Sun-Young Rha; Neeraj Agarwal; Christian Kollmannsberger; Brian I Rini; Toni K Choueiri Journal: Lancet Oncol Date: 2013-01-09 Impact factor: 41.316
Authors: Andrew W Silagy; Roy Mano; Kyle A Blum; Renzo G DiNatale; Julian Marcon; Satish K Tickoo; Eduard Reznik; Jonathan A Coleman; Paul Russo; A Ari Hakimi Journal: Urology Date: 2019-11-11 Impact factor: 2.649